FENETRADIL is a coronary dilator.

Diphenan is p-benzyl-phenyl-carbamate. Various workers have reported that diphenan will rid children of oxyurids and it has been claimed to be nontoxic and tasteless and to have the advantage of being a vermicide as opposed to a vermifuge. An attempt has been made to assess the efficacy of diphenan as a vermicide. Diphenan was given far in excess of the normal dosage. Subsequent examnation showed few cures and these mostly in lightly infested children. The condition of many was unchanged and that of some worse after treatment. No toxic reactions were encountered. Moreover, diphenan was found to have no detectable anthelmintic effect when given in high dosage in the treatment of enterobiasis.

Dioxadilol is benzodioxane derivative. It has beta-adrenolytic activity. Dioxadilol is antihypertensive, antianginal and antiarrhythmic agent but less potent than propranolol.

Diprobutine, or tripropylmethylamine, is a pharmacological agent with rather unusual anti-Parkinsonian activity. In experimental animals, it causes general arousal with stimulation of locomotor activity, antagonizes neuroleptic-induced catatonia and blocks nicotine-elicited convulsions. In vitro, diprobutine does not interact directly with either dopaminergic, noradrenergic, serotonergic or muscarinic brain binding sites. Diprobutine binds to the high affinity allosteric site for noncompetitive blockers on T. marmorata acetylcholine receptor. Diprobutine blocks the tonic crisis induced by nicotine. A pharmacological action of diprobutine as blocker of the ionic channel associated with brain nicotinic receptors.

Disulergine is the synthetic 8 alpha-amino ergoline. Disulergine is the dopamine D2 receptor agonist and prolactin release inhibitor. Disulergine was as potent as dopamine in inhibiting growth hormone release but, in contrast to dopamine, was nearly ineffective in stimulating the secretion of the hormone.

Ditolamide is uricosuric drugs developed for the control of hyperuricemia in patients with gout.

Ricasetron (BRL 46470) is a selective serotonin 5-HT3 receptor antagonist. This compound was found to be a potent anxiolytic agent and have antiemetic (effective against vomiting and nausea) effects when tested in animal models. Moreover, this drug was reported to have less side effects than benzodiazepines (used for anxiety). Ricasetron was not further developed for medical use.

Cariporide is a selective sodium-hydrogen antiporter inhibitor patented by a pharmaceutical company Hoechst A.-G. for treatment myocardial ischemia-reperfusion injury. The sodium-hydrogen exchanger is an important player in the pathophysiology of myocardial ischemia-reperfusion injury. The accumulation of hydrogen ions in the myocyte cytosol; during ischemia creates a proton gradient that promotes the efflux of hydrogen ions in exchange for the influx of sodium ions. This sodium buildup can secondary activates the sodium-calcium exchanger to operate in the reverse mode, resulting in a net calcium accumulation in myocyte cytosol, which leads to dysfunction and cell death. By inhibiting sodium-hydrogen exchange, Cariporide can prevent the accumulation of calcium in the cytosol, therefore reduce the infarct size. In clinical trials, Cariporide shows a statistically significant decline in myocardial infarction but increases mortality. Due to the increase in mortality, cariporide did not pass clinical trials.

Divabuterol or terbutaline dipivalate is a prodrug of terbutaline. The half-life of terbutaline dipivalate in human plasma is less than five minutes. Therapeutically, most forms of terbutaline can be used as bronchodilators in antiasthmatic treatment, as smooth muscle relaxants to treat premature labour (uterine relaxant) and for a number of other indications.